Correlation Engine 2.0
Clear Search sequence regions


  • african american (1)
  • benzoates (2)
  • case report (2)
  • cornea (1)
  • corneal edema (7)
  • female (1)
  • glaucoma (2)
  • humans (1)
  • patients (1)
  • solutions (2)
  • uveitis (2)
  • woman (1)
  • Sizes of these terms reflect their relevance to your search.

    Rhopressa (netarsudil) has recently been added to the arsenal of treatment for open-angle glaucoma. It is an effective norepinephrine transporter and Rho-associated protein kinase (ROCK) inhibitor used to decrease intraocular pressure (IOP), with the most common side effect being conjunctival hyperemia. We report a unique case of Rhopressa-induced corneal edema in a 79-year-old African-American woman, which resolved after discontinuation. She had a history of smoking one cigarette per day and did not consume alcohol. She had no history of corneal edema or uveitis. Previous case reports have documented patients with Rhopressa-induced corneal edema; however, they have all had a preexisting history of corneal edema or uveitis. We believe that this is a unique case of Rhopressa-induced corneal edema in a relatively healthy eye. While Rhopressa is effective in managing glaucoma, there may be effects of treatment that are still unknown. We will discuss clinical findings of our case, along with a review of previous literature on Rhopressa and novel ROCK inhibitors. We hope that we can add to the existing body of literature and invite further investigation of Rhopressa and ROCK inhibitors and their effects on the cornea.

    Citation

    Matthew J Chu, Michael Song, Trisa Palmares, Alice Song, Julia Song. Rhopressa-induced corneal edema: a case report. Journal of medical case reports. 2021 Apr 02;15(1):182

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33810801

    View Full Text